Last updated: 2026-09-10 21:19:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Solid Biosciences Inc. (SLDB) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $9.07, with a market capitalization of $1.06B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.79 to $11.45. This page covers its latest market performance, valuation, price trends and company information.
$1.06B | |
$9.36 | |
$822.60 | |
$1.81 | |
$9.54 | |
697.12K | |
1.58M | |
-- | |
$11.45 | |
$3.79 | |
-- | |
-- |
Solid Biosciences Inc. (SLDB) is trading at $9.08 in after-hours trading as of 2026-09-10 20:54:00, down 4.87% ($0.46) from the regular-session close of $9.54.
After-hours trading shows how investors are pricing SLDB after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Solid Biosciences Inc. (SLDB) moved from $9.58 to $9.07, representing a decline of 5.29% ($0.51).
The stock traded between $9.01 and $10.48 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 713.88 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 69.0%
SLDB is currently trading at $9.07, placing it 69.0% of the way from its 52-week low of $3.79 to its 52-week high of $11.45. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 121 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Solid Biosciences Inc. (SLDB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.